Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices.
about
Neuropeptide S receptor 1 (NPSR1) activates cancer-related pathways and is widely expressed in neuroendocrine tumors.Immunohistochemical quantification of the vitamin B12 transport protein (TCII), cell surface receptor (TCII-R) and Ki-67 in human tumor xenografts.Endoscopic biopsy in gastrointestinal neuroendocrine neoplasms: a retrospective studyClinical and pathological features of non-functional neuroendocrine tumors of pancreas: a report from iranProposal for a standardized pathology report of gastroenteropancreatic neuroendocrine tumors: prognostic significance of pathological parametersOsteoactivin (GPNMB) ectodomain protein promotes growth and invasive behavior of human lung cancer cells.Diagnostic performance and factors influencing the accuracy of EUS-FNA of pancreatic neuroendocrine neoplasms.An international Ki67 reproducibility study.Advancements in pancreatic neuroendocrine tumors.Spatial intratumoral heterogeneity of proliferation in immunohistochemical images of solid tumors.Synaptophysin-Ki67 double stain: a novel technique that improves interobserver agreement in the grading of well-differentiated gastrointestinal neuroendocrine tumorsPrognostic markers in smear preparations for pancreatic endocrine neoplasms: A cytomorphologic study and statistical analysis of 20 potential prognostic features.Classification of pulmonary neuroendocrine tumors: new insights.Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment?Comparison between Manual and Automated Methods for Ki-67 Immunoexpression Quantification in Ameloblastomas.
P2860
Q30433526-050C262E-0206-42DF-97BD-06BEB48BF95BQ33702468-53E84DAC-1DB8-4035-900D-5CF74ABAAF5AQ33961334-6198F8A1-9EA8-478F-8DB1-A96C833AEE87Q33993022-96E1A67D-775A-4833-8BF0-6AC9D2C70D3CQ36983412-764DCFEE-5899-4825-871F-D1A5EDA30410Q37046492-11585EB7-9051-47DC-A851-9218D6BDDA12Q37188249-6588A74E-5BA7-4797-902A-B78ED7D3F1B8Q37463125-702B6550-FA47-43C1-BA5D-428232F8AB13Q38125257-C6EB1B52-97BD-42E6-9183-2BADF89A3C33Q38856277-90A0C88B-9593-4317-B338-103554ACC3B6Q39022631-C1E9A5F2-E336-4F75-8CA1-3EAADADA46E5Q39301100-E346BEFC-036E-44A9-B845-3960309B4ED3Q45140096-182613C5-0175-4CC8-B166-94B45FA3B3DBQ45999443-C7584FA6-9168-4CC1-ACCF-008407338C5DQ48097270-1B07EB9C-5D74-4473-9452-9E774A4901C4Q51065570-C7DFC140-44C2-4257-B232-8390FBA17156
P2860
Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices.
@ast
Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices.
@en
Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices.
@nl
type
label
Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices.
@ast
Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices.
@en
Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices.
@nl
prefLabel
Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices.
@ast
Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices.
@en
Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices.
@nl
P2093
P1476
Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices.
@en
P2093
Heikki Helin
Johanna Arola
Jorma Isola
Satu Maria Remes
Vilppu J Tuominen
P304
P356
10.1097/PAS.0B013E3182632038
P407
P577
2012-09-01T00:00:00Z